-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
-
-
-
-
-
-
Kura Oncology to Report Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Kura Oncology (KURA)
-
-
-
-
-
-
-
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

